TOKYO–(BUSINESS WIRE)–Morinaga Milk Industry Co., Ltd. (TOKYO:2264), Japan’s leading dairy company, is pleased to announce that its proprietary probiotic strain Bifidobacterium longum subspecies. long BB536 (hereinafter referred to as Bifidobacteria long BB536) has been approved by the Brazilian Health Regulatory Agency (Agência Nacional de Vigilância Sanitária, ANVISA).This approval was granted on July 27, 2023, allowing the use of Bifidobacterium longum BB536 is found in dietary supplements and conventional foods sold in Brazil. This strain is also registered on ANVISA’s list of approved products.
Bifidobacterium longum BB536 is a clinically effective and proven multifunctional probiotic strain with over 50 years of human use and backed by more than 240 scientific studies as of March 2023. Bifidobacterium longum BB536 has been recognized globally as a leading functional probiotic ingredient with Generally Recognized As Safe (GRAS) status in the US for use in traditional foods and infant formula. It has also been approved as a “new food ingredient” in China for use in food for infants and young children under the age of three.
Recent ANVISA approvals allow Bifidobacterium longum BB536 can be used in dietary supplements and various conventional foods. At the same time, the approval states that “Bifidobacterium longum BB536 may help gastrointestinal health. “
The approval has a major impact on Morinaga Dairy’s global growth strategy. As one of the goals outlined in the company’s 10-year vision, Morinaga aims to achieve a foreign sales ratio of at least 15% by the fiscal year ending March 31, 2029. The approval is in line with the company’s commitment to expand its business overseas. International markets, including strengthening partnerships with major infant formula manufacturers and marketing dietary supplements around the world.
The Brazilian probiotic supplements market is growing rapidly, with a CAGR of approximately 9% from 2013 to 2022, and the market size will more than double to approximately USD 200 million*1
. Morinaga expects a bright future for the Brazilian market.
*1Source: Euromonitor International, August 2023
“We are pleased to announce ANVISA’s approval of BB536 for use in supplements and traditional foods in Brazil,” said Dr. Yoshihiko Ushida, General Manager, International B2B Business Unit, Morinaga Milk Industry. “This achievement underscores our commitment to producing scientifically proven, high-quality probiotics , contributing to the well-being of consumers around the world.” As Morinaga Milk continues to move forward, the company is enthusiastic about the opportunities this milestone presents.
Morinaga Dairy Co., Ltd. is one of Japan’s leading dairy companies with a century-old history in utilizing the nutritional properties and functional ingredients of dairy products. Morinaga Dairy is also an important probiotics manufacturer in the world. It is good at innovative technology and provides high-quality probiotics and functional ingredients series on a global scale. Since the 1960s, Morinaga Dairy has been researching the safety, functional health benefits and mechanism of action of the probiotic Bifidobacterium to better understand its role in maintaining human health. For more information on Morinaga Human Habitat Bifidobacteria (HRB) probiotics, please visit our website: https://morinagamilk-ingredients.com/.
Morinaga Dairy Co., Ltd.
Investor and Public Relations Department
Mitsunori Watanabe / Kajikawa Kazuaki
Nan Chunyi/ Huang Qinwen
Morinaga Milk website: https://www.morinagamilk.co.jp/english/
Content provided by Business Wire. Jinri Toutiao is not responsible for the content provided or any link related to the content. Toutiao is not responsible for the correctness, topicality or quality of the content.